Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc has demonstrated strong financial performance, with a 30% year-over-year revenue growth in fourth quarter 2024, contributing to an anticipated $370 million in revenue for 2025. The company also reported a steady 14% increase in testing volume, rising from 39,900 in the previous quarter to 45,500, indicating consistent demand for its precision medicine services. Furthermore, CareDx's financial position remains robust, with cash and investments increasing to $261 million by the end of December 2024, signaling a solid foundation for continued growth and operations.

Bears say

CareDx Inc faces significant financial risks that contribute to a negative outlook on its stock. The company's revenue generation is heavily reliant on testing services, putting it at risk if it fails to secure adequate reimbursement rates or if competitors develop superior technologies, which could lead to market share loss. Additionally, potential regulatory changes, integration challenges from acquisitions, and vulnerabilities in intellectual property protection pose considerable threats that could adversely affect CareDx’s future financial performance, as highlighted by its recent EBITDA guidance falling short of expectations and a reported net loss.

CareDx (CDNA) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 11 analysts, CareDx (CDNA) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.